The global “critical care antiarrhythmic drugs” market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others), By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”. According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million people worldwide in 2016. Atrial fibrillation (AF) is the most frequent and the most commonly observed CVD. For example, the American Heart Association estimates that AF affects around 2.2 million people in the United States.
More importantly, the incidence of AF is steadily rising. A study conducted by the Erasmus Medical Center in the Netherlands found that approximately 17.9 million people across Europe will be afflicted by AF in 2060. A similar epidemiological study conducted by researchers at the University of Arkansas revealed that in the US, between 6 million and 12 million people will suffer from AF by 2050. These projections indicate a steady rise in the demand for critical care antiarrhythmic drugs in the forthcoming decades as cardiac arrhythmia can turn fatal if not treated with effective medication in time.
Click here to get the short-term and long-term impact of COVID-19 on this market.
Please visit: https://www.fortunebusinessinsights.com/critical-care-antiarrhythmic-drugs-market-104703
Highlights of the Report:
- In-depth analysis of various insights, namely, Critical Care Antiarrhythmic Drugs Market trends, growth drivers, opportunities, and other related challenges.
- Comprehensive details of key market players, their core competencies, and Critical Care Antiarrhythmic Drugs Market share.
- The potency of suppliers and buyers to make better business decisions.
- Lists out the market size in terms of volume.
Key Players Operating in The Critical Care Antiarrhythmic Drugs Market Include:
Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:
- Amomed Pharma GmbH (Vienna, Austria)
- Mayne Pharma (Salisbury South, Australia)
- Sanofi (Paris, France)
- Mylan N.V. (Pennsylvania, U.S.)
- Pfizer Inc. (New York, U.S.)
- Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)
- GlaxoSmithKline plc (London, U.K.)
- Baxter International Inc. (Deerfield, U.S.)
- Novartis AG (Basel, Switzerland)
Growing Importance of Heart Health amid COVID-19 to Boost the Market
The COVID-19 pandemic has reiterated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at high risk of contracting the coronavirus. Early evidence from China’s Hubei and Wuhan provinces shows that 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania in July 2020 revealed that the onset of the COVID-19 infection was associated with a high incidence of cardiac arrhythmias in patients. While the coronavirus is not solely responsible for the occurrence of cardiac abnormalities, the infection, in many cases, has worsened the preexisting conditions, leading to higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, heightened the adoption of critical care anti-arrhythmogenic drugs worldwide. The global market has, as a result, registered a CAGR of 12.9% in 2020.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/critical-care-antiarrhythmic-drugs-market-104703
Regulatory Backing to Novel Drug Formulations to Ensure Lasting Market Growth
Active support from regulatory bodies to novel formulations of drugs for antiarrhythmic treatment is fueling the critical care antiarrhythmic drugs market growth. Such backing from regulators is encouraging key players to innovate and scale up production, enabling them to cater to the widening demand for effective treatments for cardiac issues.
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Key Insights
- Epidemiology of Arrhythmias, For Key Countries/ Regions
- Prevalence of Cardiovascular Disease – For Key Countries/ Regions
- Pipeline Analysis
- New Product Launches
- Key Industry Developments – Partnerships, Mergers & Acquisitions
- Impact of COVID-19 Pandemic for Critical Care Antiarrhythmic Drugs Market
- Global Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Beta Blockers
- Calcium Channel Blockers
- Sodium Channel Blockers
- Potassium Channel Blockers
- Others
- Market Analysis, Insights and Forecast – By Disease Type
- Supraventricular arrhythmias
- Ventricular arrhythmias
- Others
- Market Analysis, Insights and Forecast – By Countries/ Sub regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027
- Key Findings / Summary
- Market Analysis – By Drug Class
- Beta Blockers
- Calcium Channel Blockers
- Sodium Channel Blockers
- Potassium Channel Blockers
- Others
- Market Analysis, Insights and Forecast – By Disease Type
- Supraventricular arrhythmias
- Ventricular arrhythmias
- Others
- Market Analysis, Insights and Forecast – By Country
- S.
- Canada
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/critical-care-antiarrhythmic-drugs-market-104703
Report Focus:
- Extensive product offerings
- Customer research services
- Robust research methodology
- Comprehensive reports
- Latest technological developments
- Value chain analysis
- Potential Critical Care Antiarrhythmic Drugs Market opportunities
- Growth dynamics
- Quality assurance
- Post-sales support
- Regular report updates
Reasons to Purchase this Report:
- Comprehensive analysis of the Critical Care Antiarrhythmic Drugs Market growth drivers, obstacles, opportunities, and other related challenges.
- Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
- Identifies market restraints and boosters.
- Identifies all the possible segments present in the market to aid organizations in strategic business planning.
KEY QUESTIONS ANSWERED:
- What is the market size and growth rate of the global and regional market by various segments?
- What is the market size and growth rate of the market for selective countries?
- Which region or sub-segment is expected to drive the market in the forecast period?
- What Factors are estimated to drive and restrain the Critical Care Antiarrhythmic Drugs Market growth?
- What are the key technological and market trends shaping the market?
- What are the key opportunities in the market?
- What are the key companies operating in the market?
- Which company accounted for the highest market share?
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
